Exelixis (NASDAQ: EXEL) is set to give its latest quarterly earnings report on Tuesday, 2025-11-04. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will ...

Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to buy. On October 21, Exelixis, Inc. (NASDAQ:EXEL) ...

As previously reported, Guggenheim downgraded Exelixis (EXEL) to Neutral from Buy and removed the firm’s previous $45 price target on the shares.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer ...

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In this up-and-down market, being able to spot stock trends means the difference between making money and keeping it. In this ...

Schwab reported a fairly good Q3 ’25 quarter, with net revenue growing 16% y-o-y, pre-tax income growing 25%, and EPS growing ...

Globe Investor value reports provide a daily price target for more than 9,000 stocks on the TSX, Nasdaq, and NYSE. Used by Bay Street pros, advisors and Canadians who invest on their own, they help ...

According to TipRanks.com, Rama is a 3-star analyst with an average return of 1.8% and a 46.7% success rate. Rama covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics ...

Texas Longhorns quarterback Arch Manning didn't choose to be the center of the college football universe. He didn't choose to ...

Save big on Thanksgiving with Sam’s Club finds under $10. Easy apps, sides, drinks and desserts will simplify holiday prep ...